Laddar populära aktier...
Medical cannabis has been legal in Denmark under a pilot program since 2018 during a trial period that was set to expire in December 2025.
STENOCARE A/S (“STENOCARE” or the “Company”) continues to experience tough market conditions in Denmark because of increased competition and...
STENOCARE published on November 5th the company’s Q3-report for 2024.
STENOCARE announced on October 14th that the company has updated the sales guidance for 2024, from gross sales of DKK 6-8m, which are now ex...
STENOCARE A/S (“STENOCARE” or the “Company”) has executed on several strategically important milestones during H1-24, including approval of ...
STENOCARE published on August 21st the company’s Q2-report for 2024.
STENOCARE announced on June 17th that the company is planning an expansion into Canada together with North America industry experts, which m...
Med ett nytt godkännande i Danmark för en THC/CBD medicinsk cannabisolja har Stenocare återtagit positionen som enda leverantör av två av de...
STENOCARE announced on May 23rd that the company’s premium product, the Astrum oil, is ready for launch on the Australian market.
With a new THC/CBD medical cannabis oil approved, which is ready for sales under the Danish pilot program, STENOCARE A/S (“STENOCARE” or the...
STENOCARE published on May 2 the company’s Q1-report for 2024, showing progress.
During 2023 STENOCARE delivered record in gross sales amounting to DKK 6.
STENOCARE published on February 22nd its year-end report for 2023.
STENOCARE announced on December 14th that the company has entered into a new partnership agreement with Quest Biotech Pharma (“QBP”), aimed ...
STENOCARE announced on November 23rd that the company has signed agreements that will make a new product, a Balanced 25-25 oil, available fo...
The number of patients continued to grow strongly during Q3-23 for STENOCARE A/S (“STENOCARE” or “the Company”) which resulted in actual sal...
STENOCARE published on November 9th its Q3-report for 2023.
STENOCARE announced on November 6th an updated guidance for 2023 and 2024 as well as sales in Q3-23, amounting to DKK 2.
STENOCARE announced on September 18th a market update highlighting progress in several areas, including increased market share in Denmark, a...
In Q2-23, STENOCARE delivered a sales growth of 279% Y-Y, amounting to DKK 1.
Stenocare published on August 17 its Q2-report for 2023.
With the Q1-report presented, it is clear that STENOCARE A/S (“STENOCARE” or the “Company”), has laid the groundwork for future scale-up, fo...
STENOCARE published on June 20 its Q1-report for 2023.
STENOCARE announced on May 30th that the company has developed an IT-platform that enables doctors to launch and operate Online Clinics.
STENOCARE genomför nu en företrädesemission fram till den 8 juni.
STENOCARE announced on May 25th, that a new medical cannabis oil product has received approval from the Federal Institute for Drugs and Medi...
On May 15, 2023, STENOCARE announced that the company intends to carry out a preferential Rights Issue of shares and warrants of series TO 1...
After entering three new markets in 2022, STENOCARE delivered products to a total of five countries during Q4-22, leading to net sales amoun...
STENOCARE published on February 23 its year end report for 2022.
STENOCARE announced on Monday, January 9th, that products were delivered to its five markets during Q4-22, corresponding to net sales of DKK...
Analyst Group has entered into an agreement with STENOCARE on commissioned research, including e.
